Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
ID: 352965Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352965

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-037.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Mar 14, 2024 12:00 AM
  4. 4
    Due May 20, 2024 12:00 AM
Description

The Food and Drug Administration (FDA) has posted a federal grant opportunity titled "Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional". This grant aims to address topics related to the use of digital health technologies (DHTs) for remote data acquisition in clinical investigations to support drug development.

The purpose of this grant is to support the procurement of digital health technologies that can be used in clinical investigations for drug development. These technologies will enable remote data acquisition, allowing researchers to collect data from patients without the need for in-person visits.

The grant does not require cost sharing or matching requirements and falls under the category of funding activity for Food and Nutrition. It is a cooperative agreement type of funding instrument. The grant has an award ceiling of $1,100,000 and an estimated total program funding of $1,100,000. Only one award is expected to be granted.

The eligibility for this grant is open to others, including foreign organizations and non-domestic entities. Non-domestic components of U.S. organizations are also eligible to apply. The grant provides additional information on eligibility for foreign organizations as defined in the HHS Grants Policy Statement.

The closing date for this grant opportunity is May 20, 2024, and the archive date is June 19, 2024. For more information and to apply, interested applicants can visit the following website: RFA-FD-24-037 Funding Opportunity Announcement.

For any inquiries or further assistance, interested applicants can contact Zahara Graves, the grantor, at zahara.graves@fda.hhs.gov.

Point(s) of Contact
zahara.graves@fda.hhs.gov
Files
Title
Posted
RFA-FD-24-037.html
4/20/2024
Similar Opportunities
Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional". This funding opportunity falls under the category of Consumer Protection and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of the impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products. The grant has an award ceiling of $500,000 and an award floor of $250,000. It is expected that there will be 2 awards given. The eligible applicants for this grant opportunity are unrestricted, meaning any applicant organization may submit an application. However, each application must be scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. For more information and to apply for this grant opportunity, you can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The last updated date for this grant opportunity is November 30, 2023.
Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed". This grant aims to develop and test an AI- or ML-based algorithmic Real-World Data (RWD) model for post-market surveillance of complex generic drug products. Complex generic drug products are becoming more prevalent in the generic marketplace and may have distinct user interface differences compared to reference listed drug (RLD) products. This funding opportunity seeks to address the need for a modernized post-market surveillance approach to compare clinical outcomes between complex generic products and their corresponding RLD products. The goal is to monitor for potential issues with therapeutic equivalence and inform regulatory decision making. The use of real-world data combined with machine learning (ML) and/or artificial intelligence (AI) can help efficiently identify post-market signals in an automated and repeatable manner. This will facilitate timely regulatory action. The FDA is looking for innovative proposals to develop and test an AI- or ML-based algorithmic RWD model that can effectively assess post-market clinical outcomes in patients switching among complex generic drug products and reference listed drugs. The grant has a funding ceiling of $300,000 and a floor of $300,000. It is expected that one award will be granted. The grant does not require cost sharing or matching. The category of funding activity is consumer protection, and the opportunity falls under the discretionary category. The grant is forecasted for the fiscal year 2024. Applicant organizations may submit more than one application, as long as each application is scientifically distinct. However, duplicate or highly overlapping applications will not be accepted. The FDA will not accept new applications that are submitted before the issuance of the summary statement from the review of an overlapping new or resubmission application. Similarly, resubmission applications cannot be submitted before the issuance of the summary statement from the review of the previous new application. Additionally, applications with substantial overlap with another application pending appeal of initial peer review will not be accepted. For more information and to apply for the grant, interested parties can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or by phone at 240-338-7494.
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Active
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)". This grant aims to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). DTx refers to clinical-grade mobile, web, or other software-based platforms designed to deliver safe and effective treatments for SUDs. The goal is to generate new, FDA authorized, disseminated treatments for SUDs by moving DTx to their next step in the development process. This opportunity allows for the focus on pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. Eligible applicants include various institutions and organizations. The deadline for application submission is November 19, 2026. For more information and to apply, visit the following link: [Developing Digital Therapeutics for Substance Use Disorders Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-24-064.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required". This grant aims to fund clinical trials of products that evaluate efficacy and/or safety in order to support a new indication or change in labeling to address unmet needs in rare diseases or conditions. The FDA expects that by funding collaborative, efficient, and/or innovative clinical trials, the number of approved treatments for rare diseases will increase, thereby having a positive impact on rare disease drug development. The grant does not require cost sharing or matching and falls under the category of Science and Technology and other Research and Development. The grant has a closing date of September 22, 2024, and the award ceiling is $650,000, with a minimum award floor of $200,000. It is expected that 20 awards will be granted. Eligible applicants include various types of organizations such as higher education institutions, nonprofits, for-profit organizations, governments, and foreign institutions. For more information, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html). For any inquiries, the grantor contact is Shashi Malhotra, a Grants Management Specialist, who can be reached at shashi.malhotra@fda.hhs.gov or by phone at 2404027592.
Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)". This grant falls under the category of Consumer Protection and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this funding opportunity is to support research and development in non-invasive technologies, specifically quantitative tomography-based methods, to evaluate the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The funded work aims to develop an accurate, sensitive, and reproducible approach to measure the amount of drug present in the skin at various depths below the surface. This approach will be used to monitor the cutaneous pharmacokinetics (PK) of the drug over time. The ultimate goal is to develop a scientifically valid in vivo cutaneous PK-based approach that can efficiently demonstrate the bioequivalence (BE) of topical products. The grant has an award ceiling and floor of $250,000, and it is expected that one award will be made. The eligibility for this grant is unrestricted, meaning any applicant organization can apply. However, each application must be scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. For more information or to apply for this grant opportunity, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or by phone at 240-338-7494. The deadline for this grant is forecasted to be in the fiscal year 2024.